SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurobiological Tech (NTII)
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
1494 40 0 NTII
Emcee:  Miles Rhyne Hoffman, CFA Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1344Neurobiological Technologies, Inc. and the Food And Drug Administration Agree onmopgcw-8/22/2005
1343FDA Rejects Forest Labs Expanded Label Monday July 25, 1:11 pm ET FDA Denies John McCarthy-7/25/2005
1342PAION and Lundbeck Partner on Phase III Compound Desmoteplase for Acute Stroke John McCarthy-7/14/2005
1341Neurobiological Technologies Inc. Chooses SCIREX Corporation as CRO to Manage Phsim1-6/2/2005
1340Neurobiological Technologies Adopts Stockholder Rights Plan Friday May 20, 8:45 sim1-5/20/2005
1339Neurobiological Technologies, Inc. Reports Third Quarter Results Tuesday May 10,mopgcw-5/10/2005
13384th Quarter Namenda Sales - Sales of Namenda amounted to approximately $93 millJohn McCarthy-4/6/2005
1337Neurobiological Technologies, Inc. Reports on an End of Phase II Meeting with thsim1-3/14/2005
1336Memantine and Catatonic Schizophrenia ajp.psychiatryonline.org SEVERE EDIT MJohn McCarthy-3/3/2005
1335Pre Phase III meeting soon with FDA At a Wells Fargo Securities conference todaJohn McCarthy-3/3/2005
1334UK regulator could withdraw Alzheimer's drugs 2 Mar 2005, 15:09 GMT - The John McCarthy-3/3/2005
1333Report from Scimitar Equity Research Neurobiological Technologies, Inc. Royaltsim1-2/10/2005
1332Neurobiological Technologies Receives FDA Fast-Track Status For Anti-Stroke TreaJohn McCarthy-1/28/2005
1331Product Development Milestones Source: jmdutton jmdutton.com <EDIT> TaJohn McCarthy-1/12/2005
1330Morgan Stanley about Namenda .... We have analyzed the trends for the AlzheimerJohn McCarthy-1/11/2005
1329Memantine as a neuroprotective treatment in schizophrenia • Authors’ reply RandsJohn McCarthy-1/4/2005
1328Two new Trials for Memantine: Phase 2 Evaluation of the Safety and Efficacy ofJohn McCarthy-1/4/2005
1327Trial - The Utility of Namenda® in the Treatment of Primary Progressive AphJohn McCarthy-12/31/2004
1326I have a copy of the Powerpoint Presentation from the stockholders meeting. PleJMarcus-11/24/2004
1325Thanks so much for the clarification, Harry. I may have misinterpreted what DavJMarcus-11/21/2004
1324Marc: Some of the info presented at the NTI meeting is incorrect: <<And NeuroInvestment-11/21/2004
1323That was excellent, Thankyouscott mcdowell-11/20/2004
1322Here is the second and final installment, which begins with a continuation of StJMarcus-11/20/2004
1321Marc .... Thank you very much for the overview. I posted a link to it on the John McCarthy-11/20/2004
1320RICHMOND, Calif., Nov 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- NeurobioloJMarcus-11/19/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News